Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Interesting

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Jun 19, 2022 2:04pm

125 Views

Post# 34767643

RE:Interesting

Ryeman40 wrote: https://worldwide.espacenet.com/publicationDetails/biblio?CC=WO&NR=2022115952A1&KC=A1&FT=D&ND=3&date=20220609&DB=EPODOC&locale=en_EP&fbclid=IwAR1rD12AEleEx7sdA-ZHePmKztAJTdW4PXUN9XXpLOJeIBGvoEx-IlawPTs

Yes - he's co-chair of our scientific advisory board and he likely works closely with Dan at the University of Calgary - where a lot of our 429/IBD work seems to have been done.

Respiratory Diseases is one of the items in our product funnel and we know they are looking in this direction.

Sounds good !

<< Previous

Bullboard Posts

Next >>

10 common investing mistakes to avoid